AstraZeneca on Monday said it supported ATAGI’s advice, adding that regulatory authorities around the world agreed that the benefits of using the vaccine significantly outweighed the risks across all adults age groups. Australia has abundant stocks of locally-manufactured AstraZeneca, but imported Pfizer is in short supply.
The Australian Technical Advisory Group on Immunisation, known as ATAGI, recommended on July 13 that adults under the age of 60 take Pfizer because of the increased risk in younger adults of blood clotting caused by the AstraZeneca vaccine. Pfizer and AstraZeneca are the only COVID-19 vaccines registered in Australia. But with a delta variant cluster growing in Sydney since mid-July, ATAGI on Saturday recommended adults in Australia’s largest city as young as 18 “should strongly consider getting vaccinated with any available vaccine,” including AstraZeneca. Because Australia has been relatively successful in containing COVID-19 outbreaks before the more contagious delta variant arrived in Sydney with a U.S. air crew, many Australians are prepared to wait months for Pfizer rather than risk AstraZeneca.
___ MORE ON THE PANDEMIC:
— Malaysia’s Parliament opens after 7 months, emergency to end Aug. 1 — German business confidence sinks as virus clouds outlook — Europe’s summer tourism outlook dimmed by variants, rules
— Positive virus tests knock Rahm, DeChambeau out of Olympic golf tournament — Tunisian president fires premier, freezes parliament’s activities after violent protests over economy, virus spread ___
The News Highlights
- Latest: AstraZeneca supports Australian vaccine recommendations
- Check the latest update on business news
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week